AC Immune Story

<div class='circular--portrait' style='background:#FF0000;color: #F5FFFA;font-size:4em;'>AI</div>
ACIU -- USA Stock  

USD 4.80  0.35  6.80%

AC Immune Earnings per Basic Share are comparatively stable at the moment as compared to the past year. AC Immune reported Earnings per Basic Share of 0.64 in 2019. Earnings per Diluted Share is likely to grow to 0.69 in 2020, whereas Market Capitalization is likely to drop slightly above 572.8 M in 2020. There are many examples of share prices decreasing after an abrupt shift in one of the primary indicators. Let's review some of AC Immune's important ratios. We will look into reasons why it is still very possible for the company to generate above-average returns. The company almost neglects market trends. We can now break down AC Immune as a potential investment option for your portfolios.
Published over a month ago
View all stories for AC Immune | View All Stories
Will stockholders exit AC Immune (NASDAQ:ACIU) in September?
We provide trade recommendation to complement the latest expert consensus on AC Immune SA. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at this moment. AC Immune dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include AC Immune income statement, its balance sheet, and the statement of cash flows. Potential AC Immune investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AC Immune investors may use each financial statement separately, they are all related. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AC Immune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of AC Immune fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of AC Immune performance into the future periods or doing a reasonable stock valuation. The intrinsic value of AC Immune shares is the value that is considered the true value of the share. If the intrinsic value AC Immune is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares AC Immune. Please read more on our fundamental analysis page.

What is AC Immune Asset Breakdown?

AC Immune SA reports assets on its Balance Sheet. It represents the amount of AC Immune resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect AC Immune volatility, please check the breakdown of all its fundamentals

Are AC Immune Earnings Expected to grow?

The future earnings power of AC Immune involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of AC Immune factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. AC Immune stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of AC Immune expected earnings.

AC Immune Gross Profit

AC Immune Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing AC Immune previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show AC Immune Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Breaking it down

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of AC Immune is not uncomon. Many companies such as AC Immune have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of AC Immune is distributed among investors.

Ownership Allocation

AC Immune SA secures a total of seventy-one million eight hundred sixty thousand outstanding shares. AC Immune SA shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors25.32

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AC Immune has an asset utilization ratio of 13.92 percent. This implies that the company is making $0.14 for each dollar of assets. An increasing asset utilization means that AC Immune SA is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
238.9 M
Current Assets238.92 Million97.16
Assets Non Current6.99 Million2.84

Will AC Immune spontaneously start a bounce back?

AC Immune newest variance boosts over 18.99. As of the 2nd of August, AC Immune owns the Standard Deviation of 4.36, coefficient of variation of (4,964), and Market Risk Adjusted Performance of 0.3318. AC Immune SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Strictly speaking, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We have collected data for nineteen technical drivers for AC Immune, which can be compared to its peers in the sector. Please confirm AC Immune SA coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if AC Immune SA is priced fairly, providing market reflects its prevailing price of 6.53 per share. Given that AC Immune SA has jensen alpha of (0.046052), we suggest you to validate AC Immune's latest market performance to make sure the company can sustain itself sooner or later.

Our Takeaway on AC Immune Investment

Whereas many of the other players in the biotechnology industry are either recovering or due for a correction, AC Immune may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current AC Immune valuation and our trade advice on AC Immune is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AC Immune.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of AC Immune SA. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to